The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
Subscribe To Our Newsletter & Stay Updated
